Blaming Flight Cancellations for Iran's Medicine Shortage Is a Convenient Lie

Blaming Flight Cancellations for Iran's Medicine Shortage Is a Convenient Lie

Every time geopolitical friction flares up in West Asia, the exact same press release gets dusted off, polished, and fed to a compliant media cycle. This week, the headline reads that New Delhi is actively facilitating the supply of life-saving medicines to Tehran amid "flight connectivity challenges."

Buy that framing if you want. Most supply chain observers do. It paints a tidy, heroic picture: benevolent bureaucrats fighting against grounded airplanes and closed airspaces to ensure cancer patients and diabetics get their doses.

It is also complete nonsense.

Blaming flight connectivity for pharmaceutical bottlenecks between India and Iran is like blaming a flat tire when your engine has been ripped out of the chassis. Direct commercial air routes between Mumbai and Tehran are nice to have. Losing them creates friction. They are not, however, the reason critical active pharmaceutical ingredients (APIs) and finished formulations sit stranded in customs warehouses or never leave Hyderabad in the first place.

If you have ever actually moved temperature-controlled biologics across sanctioned corridors, you know the truth. Airplanes do not move on jet fuel alone. They move on letters of credit, marine and aviation hull insurance, and correspondent banking clearance. When those three pillars collapse, a Boeing 777 is just an expensive aluminum tube sitting on the tarmac.

The Humanitarian Exemption Myth

The lazy consensus surrounding pharmaceutical trade with Iran relies on a fundamental misunderstanding of international sanctions law. Whenever supply drops, commentators point to airspace closures or regional tensions, carefully avoiding the elephant in the room: the financial architecture governing so-called "humanitarian" trade.

Technically, food and medicine are exempt from United States and European Union secondary sanctions. Washington says so. Brussels says so. The Office of Foreign Assets Control (OFAC) publishes sprawling General Licenses explicitly permitting the sale of agricultural commodities, medicine, and medical devices to Iranian entities.

On paper, the door is wide open. In practice, walking through that door requires a bank willing to process the transaction, an insurer willing to underwrite the cargo, and a freight forwarder willing to put its corporate neck on the chopping block.

I have watched mid-sized pharmaceutical exporters in Gujarat spend eighteen months and hundreds of thousands of dollars in legal compliance fees trying to execute a single "exempt" shipment of oncology drugs. They had the product. They had an Iranian buyer with cash in hand. They even had cargo space booked through a third-country hub.

The deal died in a compliance department in Zurich.

Why? Because global financial institutions operate on a principle called de-risking. If a European or Asian correspondent bank processes a dollar—or even a euro—linked to an Iranian counterparty, the potential fine from US regulators runs into the hundreds of millions, if not billions, of dollars. The profit margin on clearing a $2 million pharmaceutical invoice is a fraction of a percent. No risk officer on earth is going to sign off on a transaction where the upside is $5,000 and the downside is losing their New York dollar-clearing license.

So when government officials announce they are "facilitating" medicine supplies by working around flight cancellations, they are treating a symptom while ignoring the disease. You can charter a fleet of Antonovs tomorrow morning. If the settlement mechanism is broken, those planes will fly empty.

Why Air Cargo Was Never the Real Bottleneck

Let us look at the actual logistics of Indo-Iranian trade. Before the latest wave of airspace disruptions, how did bulk pharmaceuticals actually move between the two countries?

Finished dosage forms—high-value, low-weight items like monoclonal antibodies, insulin pens, and specialized chemotherapy vials—frequently traveled via belly-hold cargo on passenger airlines like Mahan Air, Iran Air, or connecting Gulf carriers through Dubai and Doha. When direct flights suspend operations due to security advisories or airspace restrictions, that immediate capacity vanishes.

That much is real. Nobody is denying that sudden route cancellations disrupt cold-chain schedules. Pharmaceuticals requiring strict 2°C to 8°C thermal stability cannot sit on a humid tarmac in Sharjah waiting for a connecting flight that might not depart.

Yet treating this as a mere "connectivity challenge" ignores two massive realities of pharmaceutical freight:

  1. The Bulk Reality: The vast majority of India's pharmaceutical exports to Iran—measured by volume—are not fragile biologics flying business class in active cooling containers. They are bulk APIs, excipients, and generic tablets. These move by sea, primarily from Nhava Sheva (Jawaharlal Nehru Port) directly to Bandar Abbas. The transit time across the Arabian Sea is roughly four to five days. Sea freight does not care about NOTAMs (Notices to Airmen) or closed civilian flight corridors over the Persian Gulf.
  2. The Hub Workaround: Even for urgent, temperature-sensitive air freight, the global aviation network is remarkably fluid. Freight forwarders routinely route cargo through Istanbul, Doha, Muscat, or Yerevan when direct lanes close. The physical infrastructure to move a pallet of medicine from Bengaluru to Tehran exists regardless of whether Air India or IndiGo flies the route directly.

The real reason those alternative air hubs choke up is not a lack of planes. It is transshipment compliance.

When an Indian exporter routes medicine through a third-country hub like Dubai, the local ground handler and the connecting airline must screen the airway bill against their own internal sanctions matrices. Even if the cargo is 100% legal humanitarian aid, automated compliance software flags the destination code IKA (Imam Khomeini International Airport). The shipment is immediately kicked into manual review. Manual review takes days. For a biologic with a strict thermal shelf life, a 72-hour compliance hold is a death sentence for the cargo.

The Rupee-Rial Trap and the Death of Easy Settlement

To understand why "facilitation" is mostly diplomatic theater, you have to look at the payment plumbing between New Delhi and Tehran.

During the previous decade, India and Iran operated a relatively functional Rupee-Rial payment mechanism. Iran sold crude oil to Indian state refiners, depositing massive amounts of Indian Rupees into escrow accounts held at Indian banks like UCO Bank and IDBI Bank. Indian exporters—including pharmaceutical giants and Basmati rice traders—were paid directly out of those Rupee reserves. Dollars never touched the transaction. Western banks were completely bypassed.

Then came May 2019. The United States ended its Significant Reduction Exemptions (SREs) for Iranian oil buyers. India, prioritizing its broader strategic and economic ties with Washington, zeroed out its purchases of Iranian crude.

That single decision severed the artery feeding the Rupee-Rial mechanism. Without oil revenues replenishing the UCO Bank accounts, the Rupee pile evaporated. By 2022, the balances had dwindled to critical lows, leaving Indian exporters scrambling for ways to get paid.

Imagine a scenario where you are a pharmaceutical manufacturer in Hyderabad. An Iranian hospital network wants to buy $5 million worth of immunosuppressants. Your government tells you the trade is encouraged. Your conscience tells you it is vital. Now ask yourself a basic business question: How do you collect the money?

  • Wire transfer in USD? Impossible. Instant freeze.
  • Wire transfer in EUR? Virtually impossible. European banks refuse to touch Iranian-origin funds, even through the defunct INSTEX mechanism or its successors.
  • Indian Rupees? The escrow accounts are dry because India is not buying Iranian oil.
  • Barter? You can trade medicine for Iranian pistachios, saffron, or urea. Good luck paying your clinical researchers and raw material suppliers in pistachios.

This is the reality hidden behind bland diplomatic statements about "facilitating supply." When the Indian Ministry of External Affairs or the Department of Pharmaceuticals steps in to help, they are not just calling airlines to beg for cargo space. They are trying to cobble together ad-hoc payment workarounds, begging specific state-owned banks to clear individual invoices, and leaning on state-backed insurers like the Export Credit Guarantee Corporation (ECGC) to cover shipments that private underwriters will not touch with a ten-foot pole.

Answering the Questions Nobody Wants to Ask

When news breaks about medicine shortages in sanctioned nations, the public tends to ask predictable, surface-level questions. Most of the answers circulating online miss the mark entirely.

Are airlines legally banned from flying medicine to Iran?

No. Aviation sanctions target specific Iranian carriers (like Mahan Air, which is designated by the US Treasury for transporting weapons and operatives for the IRGC) and restrict the sale of aircraft parts and maintenance services to Iran. Foreign airlines are not legally prohibited from carrying humanitarian cargo into Tehran. They stop flying there because their aviation hull and liability insurers—almost all of whom are based in London, Munich, or Zurich—either pull coverage during periods of military tension or hike war-risk premiums to astronomical levels. An airline cannot legally put a plane in the air without valid insurance.

Why doesn't India just use military or government aircraft to deliver the medicine?

Because state-sponsored airlifts are emergency band-aids, not supply chains. You use a C-17 Globemaster when an earthquake flattens a city and you need to drop 50 tons of trauma kits in 48 hours. You cannot run a national healthcare system for 88 million people on military airlifts. Modern medicine requires continuous, predictable, commercial replenishment—thousands of distinct SKUs moving every single week, integrated with hospital inventory software and customs clearance brokers. Turn commercial logistics into a state-run charity operation, and you guarantee chronic shortages.

Can't Iran just manufacture its own generic drugs?

Iran actually has a surprisingly capable domestic pharmaceutical sector. Local companies produce roughly 95% of the country's basic medicines by volume. The crisis is never about basic paracetamol or standard antibiotics. The crisis is the remaining 5%—the complex biologics, specialized oncology therapies, and patent-protected treatments for rare genetic disorders—along with the imported APIs and specialized packaging materials (like Type I borosilicate glass vials) needed to make domestic drugs safe. You cannot simply whip up a biosimilar cancer therapy in a domestic lab overnight when you are cut off from global reagents and specialized filtration equipment.

The Uncomfortable Downside of "Workaround" Logistics

Here is where the contrarian reality cuts both ways. If you are an exporter or a policymaker cheering for creative workarounds to bypass banking and aviation bottlenecks, you need to recognize the toxic side effects of shadow logistics.

Every time a pharmaceutical supply chain is forced off main-line commercial rails into opaque, third-country transshipment routes and barter-based payment schemes, two things happen immediately:

First, costs explode. Routing cargo through intermediaries, paying off-market insurance premiums, and absorbing currency conversion losses through money changers in Dubai or Istanbul adds anywhere from 15% to 40% to the landed cost of the medicine. Since the Iranian government heavily subsidizes essential drugs—or struggles to fund them with a collapsing Rial—that markup directly drains the healthcare budget, meaning fewer patients get treated for the same amount of money.

Second, quality control collapses. Legitimate pharmaceutical distribution relies on unbroken visibility. You know who touched the pallet, what temperature the container stayed at, and which batch number went to which clinic. When you push trade into grey-market channels to evade banking scrutiny, you invite counterfeit operators, expired stock dumpers, and sloppy freight handlers who leave temperature-sensitive drugs sitting in unconditioned warehouses.

I have seen shipments arrive in the region with temperature data loggers conveniently missing or wiped clean. When transparency becomes a liability for getting paid, patient safety is always the first casualty.

How Real Operators Actually Move Product Across Friction Zones

If you are running supply chain operations for a pharmaceutical manufacturer, a medical device firm, or a humanitarian logistics organization, waiting for bilateral government committees to "facilitate" your shipments is a recipe for bankruptcy. Diplomats issue statements; operators move boxes.

If you want to keep critical medical goods flowing into high-friction markets without getting your company blacklisted by OFAC or losing your banking relationships, stop relying on conventional freight forwarders and start executing a different playbook:

  1. Segregate Your Legal Entities Completely: Never run sanctioned-market humanitarian trade through the same corporate subsidiary that handles your US or European commercial operations. Establish a completely ring-fenced entity with dedicated banking, separate ERP systems, and zero overlap in board directors or US-person employees. Compliance officers at Western banks look for contagion. Give them a firewall.
  2. Pre-Clear Your End-Users with Documentary Proof: Do not wait for a shipment to get stuck at a transshipment hub to prove it is humanitarian. Build a pre-vetted compliance dossier for every single shipment before it leaves your factory floor. Include the Iranian Ministry of Health import license, end-user certificates proving the buyer is a civilian hospital or licensed distributor, and detailed chemical classifications (HS codes) proving the goods have zero dual-use potential. Hand this packet to your freight forwarder and bank before booking space.
  3. Shift from Air to Temperature-Controlled Sea Freight Where Possible: Stop panicking over passenger flight cancellations. Modern active reefer containers on sea vessels maintain tighter temperature tolerances over a five-day voyage from Mumbai to Bandar Abbas than air cargo sitting on three different tarmacs during a multi-leg flight. Reserve air freight strictly for ultra-short shelf-life radiopharmaceuticals and emergency trauma supplies.
  4. Use Specialized Humanitarian Payment Channels: Stop trying to force transactions through standard commercial correspondent banks. Work exclusively with the handful of Swiss, Turkish, or Gulf financial institutions that maintain dedicated, audited humanitarian trade desks explicitly blessed by Western regulators. Yes, their compliance checks are agonizingly slow. Yes, their fees are higher. They also actually clear the money without freezing your operating capital for six months.

Stop Buying the Press Release

The next time you read a government announcement promising to "facilitate" life-saving supplies around a logistical hiccup, read between the lines.

Flight connectivity is a real operational headache. Closed airspaces force reroutes, burn extra fuel, and strain cold-chain tolerances. Nobody in the logistics business pretends otherwise.

Pretending that airline schedules are the primary wall separating Iranian patients from Indian medicine, however, is a convenient fiction. It allows Western policymakers to claim their sanctions do not hurt civilians. It allows regional governments to look proactive without confronting the reality of dollar hegemony. And it allows the global banking sector to quietly strangle legally exempt trade behind closed doors while issuing glossy sustainability reports.

Airplanes are easy to fix. You charter a different route, you pay a higher fuel surcharge, and you put the boxes in the hold.

Fixing a global financial system terrified of its own compliance rules takes a lot more than a press release. Until someone solves the banking blockade, the planes could fly every hour on the hour—and the warehouse shelves would still sit empty.

DG

Daniel Green

Drawing on years of industry experience, Daniel Green provides thoughtful commentary and well-sourced reporting on the issues that shape our world.